Arthur Gil

No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group

Thoralf Lange, Christian Niederwieser, Arthur Gil, Rainer Krahl et autres

Introduction The combination of Imatinib (IM) and hydroxyurea (HU) was explored for the treatment of chronic myelogenous leukemia (CML).Method After in vitro testing and a phase I study (n = 20), 59 patients were randomized in the IM/HU and 29 in the …

de, us, lt, jp (code pays fourni par la source)

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response

Andreas Hochhaus, Andreas Burchert, Susanne Saußele, Gabriela Maria Baerlocher et autres

Introduction: The TIGER (CML V)-study* (NCT01657604) is a multicenter, randomized phase III trial to evaluate efficacy and tolerability of nilotinib (NIL) 2*300mg/d monotherapy vs NIL 2*300mg/d + pegylated interferon α2b (Peg-IFN) 30-50μg/week as first line therapy for chronic myeloid leukemia (CML) patients …

de, ch, cz (code pays fourni par la source)

Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study

Andreas Hochhaus, Susanne Saußele, Gabriela Maria Baerlocher, Tim H. Brümmendorf et autres

Abstract Introduction: The TIGER (CML V)-study (NCT01657604) is a multicenter, randomized phase III trial to evaluate efficacy and tolerability of nilotinib (NIL) 2*300mg/d monotherapy vs NIL 2*300mg/d + pegylated interferon alpha2b (Peg-IFN) and the option to discontinue therapy after Peg-IFN maintenance as …

de, ch, cz (code pays fourni par la source)

Imatinib (im) 400mg in patients with cml1st cp results in a higher molecular response rate at 6 months compared to im/hydroxyurea. Final results of the cml2004 study. Nct 02480608

Tobias Lange, R. Krahl, U. vom Grünhagen, Haifa Kathrin Al‐Ali et autres

Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials

Susanne Saußele, Mareike Stein, Arthur Gil, Ute Kossak-Roth et autres

Abstract Introduction: With many treatment options for chronic myeloid leukemia (CML), endpoints like health-related quality of life (HRQoL) move into focus and might be essential for deciding on treatment strategies. We sought to evaluate HRQoL in CML patients who had been registered …

de (code pays fourni par la source)